Evidence map›Paper›PMID 42711693›Full record

ArticleMolecular cancer2026

A targetable dependency on nonsense-mediated decay for cellular homeostasis and immune control in small cell lung cancer.

Lucia A Torres-Fernández, Volker Boehm, Joel Kaufmann, Jonas P Becker, Maria Garcia-Marquez, Beaunelle de Bruijn, Agnieszka Rumińska, Christian Müller, Graziella Bosco, Nazanin Alavinejad and 36 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

46 authors.

Lucia A Torres-FernándezDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Volker BoehmInstitute for Genetics, Department of Biology, University of Cologne, Cologne, 50674, Germany.
Joel KaufmannDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Jonas P BeckerDivision of Immunotherapy and Immunoprevention, German CancerResearch Center (DKFZ), Heidelberg, 69120, Germany.
Maria Garcia-MarquezCenter for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, 50931, Germany.
Beaunelle de BruijnDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Agnieszka RumińskaDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Christian MüllerDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Graziella BoscoDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Nazanin AlavinejadDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Laura LovricDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Johanna I BihlerDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Hanna SchulteDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Poorya DavoodiInstitute for Immunology, University of Tübingen, Tübingen, 72076, Germany.
Anna SchöllhornInstitute for Immunology, University of Tübingen, Tübingen, 72076, Germany.
Kian R WeihrauchDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Laura KaiserDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Olta IbruliDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Fanyu LiuDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Ariadne AndroulidakiDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Nina WobstDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Marcel SchmielDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Justinas ValiulisDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Lukas MaasDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Joshua D'RozarioDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Vignesh SakthiveluDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Bianca GöbelDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Marian TouetDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, 45147, Germany.
Johannes BrägelmannDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Katja HöpkerDepartment III of Internal Medicine, Lung Cancer Group Cologne, University Hospital Cologne, Cologne, 50931, Germany.
Felix JohnDepartment I of Internal Medicine, Lung Cancer Group Cologne, Centerfor Integrated Oncology, University Hospital Cologne, Cologne, 50931, Germany.
Jürgen WolfDepartment I of Internal Medicine, Lung Cancer Group Cologne, Centerfor Integrated Oncology, University Hospital Cologne, Cologne, 50931, Germany.
Stefan KnappStructural Genomics Consortium (SGC) and Institute of PharmaceuticalChemistry, Goethe-University Frankfurt, Frankfurt am Main, 60438, Germany.
Alexander QuaasInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany.
Maria CartolanoDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Silvia von KarstedtDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Filippo BeleggiaDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Hans-Georg RammenseeInstitute for Immunology, University of Tübingen, Tübingen, 72076, Germany.
Cécile GouttefangeasInstitute for Immunology, University of Tübingen, Tübingen, 72076, Germany.
Hans A SchlößerCenter for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, 50931, Germany.
Angelika B RiemerDivision of Immunotherapy and Immunoprevention, German CancerResearch Center (DKFZ), Heidelberg, 69120, Germany.
Hans Christian ReinhardtDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, 45147, Germany.
Niels H GehringInstitute for Genetics, Department of Biology, University of Cologne, Cologne, 50674, Germany.
Martin PeiferDepartment of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany.
Roman K Thomas *Department of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany. roman.thomas@uni-koeln.de.
Julie George *Department of Translational Genomics, University of Cologne, Faculty ofMedicine and University Hospital Cologne, Cologne, 50931, Germany. jgeorge@uni-koeln.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is one of the most aggressive malignancies, characterized by rapid metastatic dissemination and poor overall survival. Despite harboring excessive alterations, expectedly resulting in immunogenic neoantigens, patients with SCLC remain largely refractory to immunotherapy. We found abundant frameshift mutations in SCLC, regarded as highly immunogenic, counterbalanced by a hyperactive nonsense-mediated decay (NMD) pathway, responsible for frameshift-mRNA degradation. NMD activity correlated with tumor mutational burden (TMB) across cancers, suggesting that SCLC and other TMB

Indexed as

Lung NeoplasmsNonsense Mediated mRNA DecaySmall Cell Lung CarcinomaAnimalsBiomarkers, TumorCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHomeostasisHumansMiceMutationBiomarkers, TumorCancer genomicsCancer immunotherapyFrameshift mutationsGenomic instabilityNeoantigenNonsense mediated decay (NMD)ProteostasisRNA surveillanceSmall cell lung cancer (SCLC)Tumor mutational burden (TMB)

Identifiers

PMID42711693
PMCPMC13551691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.